| Literature DB >> 22946585 |
Paola Corona1, Federica Gibellini, Andrea Cavalli, Puneet Saxena, Antonio Carta, Mario Loriga, Rosaria Luciani, Giuseppe Paglietti, Davide Guerrieri, Erika Nerini, Shreedhara Gupta, Véronique Hannaert, Paul A M Michels, Stefania Ferrari, Paola M Costi.
Abstract
The upregulation of pteridine reductase (PTR1) is a major contributor to antifolate drug resistance in Leishmania spp., as it provides a salvage pathway that bypasses dihydrofolate reductase (DHFR) inhibition. The structure-based optimization of the PTR1 inhibitor methyl-1-[4-(2,4-diaminopteridin-6-ylmethylamino)benzoyl]piperidine-4-carboxylate (1) led to the synthesis of a focused compound library which showed significantly improved selectivity for the parasite's folate-dependent enzyme. When used in combination with pyrimethamine, a DHFR inhibitor, a synergistic effect was observed for compound 5b. This work represents a step forward in the identification of effective antileishmania agents.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22946585 DOI: 10.1021/jm300563f
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446